BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Roche Products Limited (Roche), on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Category: PRESS RELEASE
Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
TOKYO–(BUSINESS WIRE)–Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. This will facilitate clinical studies assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease.
New PET imaging tracer helps spot signs of Alzheimer’s disease years before symptoms appear
A new positron emission tomography radiotracer has the potential to spot signs of Alzheimer’s disease years before symptoms appear.
That’s according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, which wraps up on Tuesday, June 15. The chemical compound 18F-MK6240 has been shown to effectively measure increases in brain tau, a protein commonly found in healthy brain neurons.
Scientists see potential in using the new tracer to test the impact of emerging Alzheimer’s therapies. Read More
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. Read More
Cerveau Technologies, Inc. announces Formation of Scientific Advisory Board
Cerveau Technologies, Inc. today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.
Cerveau Scientific Advisory Board Virtual Conference 2020
MK-6240 Users Group Meeting | Webinar #1 by Cerveau Technologies Inc
2020 Virtual Conference with world renowned Leaders and Scientists in the industry!
Rick Hiatt (Cerveau Technologies)
Oskar Hannson (Lund University)
Pedro Rosa-Neto (McGill University)
Keith Johnson (Harvard University)
Kuang Gong (Harvard University)
Christopher Rowe (University of Melbourne)
See the conference here
Cerveau Technologies, Inc. Announces Collaboration with University College of London
Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.
BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Enigma Biomedical Group Announces Appointment of Michael Reitermann to Their Board of Directors
TORONTO–(BUSINESS WIRE)–Enigma Biomedical Group (EBG) today announced the appointment of Michael Reitermann to their Board of Directors effective December 1, 2019
Cerveau Technologies, Inc. Announces Initiation of Japanese Phase I Study
Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome
Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand
Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease
Cerveau Technologies Inc. Signs Research Agreement with Ionis Pharmaceuticals, Inc. for Novel Tau Imaging Agent
Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent
Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan
BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the Kobe City Hospital Organisation in Japan to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Cerveau Technologies, Inc. Signs Research Agreement with Tokyo Metropolitan Institute of Gerontology, Japan
Cerveau Technologies, Inc. Signs Research Agreement with Massachusetts General Hospital
Cerveau Technologies, Inc. Signs Research Agreement with University of Pittsburgh
Cerveau Technologies, Inc. Signs Research Agreement with the University of Washington
BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the University of Washington to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Cerveau Technologies, Inc. Signs Research Agreement with KU Leuven University, Belgium
Cerveau Technologies, Inc. Signs Research Agreement with VU Medical Center Amsterdam
Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., Sign Research Agreement with Centre for Addiction and Mental Health (CAMH), Toronto
Cerveau Technologies, Inc. Signs Research Agreement with Houston Methodist
Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau’s Achievement of a Major Milestone in China Strategy
Cerveau Technologies, Inc. Announces a Partnership with Landmark Alzheimer’s Disease DIAN-TU Trial
Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging Agent
BOSTON–(BUSINESS WIRE)– Cerveau Technologies Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.
Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center
BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Cerveau Technologies Inc. Signs Collaboration Agreement with Janssen for Novel Tau Imaging Agent
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Cerveau Technologies, Inc. Announces Collaboration with Banner Health
Cerveau Technologies Inc. Signs Collaboration Agreement with H. Lundbeck A/S for Novel Tau Imaging Agent
Imanova Secures License from Cerveau Technologies, Inc. to Manufacture Investigational Tau Ligand
Cerveau Technologies, Inc. Announces Collaboration with NYU Langone Medical Center
Cerveau Technologies, Inc. Announces FDA Acceptance of Investigational New Drug (IND) for Tau Imaging Agent MK-6240
Cerveau Technologies, Inc. Collaborates With Singapore’s Clinical Imaging Research Centre
Cerveau Technologies, Inc. Signs Clinical Supply Agreement with Merck for Investigational Tau Imaging Agent
Cerveau Technologies, Inc. Executes a Binding Term Sheet with Sinotau Pharmaceutical Group for Novel Investigational Tau Imaging Agent
Cerveau Tapped for Alzheimer’s Research
Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.